MDM2 is a key ubiquitin E3 ligase for p53 and its activity is critically regulated by a set of modulators, including ARF, p300, YY1 and recently by gankyrin, an oncoprotein frequently overexpressed in human heptocellular carcinomas. We have previously shown that MDM2 binds to and promotes retinoblastoma protein (Rb) degradation. Here we show that Rb inhibits MDM2 E3 ligase activity resulting in stabilization of p53. In addition, we demonstrated that Rb inhibits MDM2-mediated p53 ubiquitination in a gankyrin-dependent manner and the Rb-gankyrin interaction is critical for Rb-induced p53 stabilization. Furthermore, acute ablation of Rb facilitates gankyrin-mediated p53 destabilization, and desensitizes cancer cells for chemotherapy-induced apoptosis. These results indicate that Rb antagonizes gankyrin to inhibit MDM2-mediate p53 ubiquitination in cancer cells and suggest that the status of both p53 and Rb is important for efficacy of cancer chemotherapy.
Introduction
Tumorigenesis involves a series of genetic alterations that lead to deregulation of cell proliferation and cell survival. The retinoblastoma protein (Rb) pathway plays a pivotal role in negatively regulating cell proliferation (Stevaux and Dyson, 2002; Sherr, 2004) . On the other hand, the ARF/MDM2-p53 pathway is responsible for regulating cell proliferation and apoptosis upon cellular insults, including DNA damage and oncogenic stress (Oren, 2003; Vogelstein and Kinzler, 2004) . Inactivation of the Rb and p53 pathways is critical for cancer development, as exemplified by the fact that over 50% of human tumors have mutations in the p53 gene (Beroud and Soussi, 1998) and frequent loss of Rb expression in human tumors (Classon and Harlow, 2002; Sherr and McCormick, 2002) .
Inactivation of p53 is also achieved by alternative pathways, such as overexpression of MDM2, a critical negative regulator that binds to p53 and promotes its ubiquitination and degradation (Haupt et al., 1997; Kubbutat et al., 1997) . It has been well established that MDM2-mediated p53 degradation is a key mechanism in both physiological and pathological settings. It is now clear that disruption of the p53-MDM2 interaction is a primary mechanism responsible for p53 stabilization upon cellular stresses (Bond et al., 2005) .
The MDM2 N terminus (aa 19-109) is responsible for binding to p53 and the MDM2 C-terminal Ring finger domain functions as an ubiquitin E3 ligase for p53 and itself (Bond et al., 2005) . Interestingly, MDM2 central acidic domain (CAD) has been shown to play an important role in p53 ubiquitination and degradation (Argentini et al., 2001; Kawai et al., 2003; Meulmeester et al., 2003) . Notably, CAD of MDM2 binds to several proteins, which either enhance MDM2 activity such as p300 (Grossman et al., 1998 (Grossman et al., , 2003 , YY1 (Sui et al., 2004) and KAP1 (Wang et al., 2005) , or attenuate MDM2 activity, such as ARF (Pomerantz et al., 1998; Zhang et al., 1998; Weber et al., 1999) . In addition, CAD contains several serine, threonine and tyrosine residues, which are targets for phosphorylation by cellular kinases including GSK3b (Kulikov et al., 2005) and CK2 (Gotz et al., 1999; Hjerrild et al., 2001) . Importantly, phosphorylation of CAD by GSK3b results in enhanced MDM2 activity in p53 ubiquitination (Kulikov et al., 2005) . Furthermore, MDM2 binds to Rb C-pocket through its CAD (Sdek et al., 2004) , and promotes Rb degradation in a proteasomedependent and ubiquitination-independent pathway (Sdek et al., 2005) .
Recently, gankyrin, an oncoprotein overexpressed in hepatocellular carcinomas, has been reported as an important player in regulation of p53 stability (Higashitsuji et al., 2000; Dawson et al., 2006) . Gankyrin binds to MDM2 at a motif (aa 412-437) in close proximity to the C-terminal Ring finger domain, and consequently, promotes MDM2-p53 interaction and facilitates p53 ubiquitination and degradation (Higashitsuji et al., 2005) . Interestingly, gankyrin also binds to Rb through its 178 LXCXE 182 motif and promotes Rb degradation in a proteasome-dependent manner (Higashitsuji et al., 2000) .
Rb plays a pivotal role in regulation of cell cycle progression, DNA damage repair, cell differentiation, senescence and apoptosis. A body of evidence indicates that crosstalk between the Rb and p53 pathways is important for regulation of cancer cell proliferation and survival (Sherr and McCormick, 2002) . Simultaneous inactivation of p53 and Rb has cooperative effects shown by increased tumor recurrence and decreased survival of patients (Xu et al., 1996; Cordon-Cardo et al., 1997) . It is well documented that p53 regulates phosphorylation and therefore the function of Rb through activation of p21 CIP1/WAF1 transcription. MDM2 has been shown to interact with Rb and promotes proteasome-mediated Rb degradation (Xiao et al., 1995; Sdek et al., 2005; Uchida et al., 2005) . Notably, MDM2 binds to both p53 and Rb, and the trimeric protein complex is important for the regulation of p53 stability and apoptotic function (Hsieh et al., 1999) . Thus, we hypothesized that the MDM2-Rb interaction is critical for regulation of p53 ubiquitination and degradation in cancer cells. To test this hypothesis, we investigated the role of Rb on MDM2-mediated p53 ubiquitination and the effects of acute knockdown of Rb on the efficacy of chemotherapy-induced cancer cell death.
Results
Deletion of the Rb-binding motif impairs the function of MDM2 on p53 ubiquitination and degradation We have previously shown that MDM2 binds to and inhibits Rb (Xiao et al., 1995) and that an 11 amino-acid module (aa 254-264) in the MDM2 CAD is necessary and sufficient for Rb binding and subsequent degradation of Rb (Sdek et al., 2004 (Sdek et al., , 2005 . It has been documented that CAD of MDM2 plays a critical role in p53 ubiquitination and degradation (Argentini et al., 2001; Kawai et al., 2003; Meulmeester et al., 2003) . We therefore examined whether deletion of this module (aa 254-264) in the MDM2 CAD affects p53 ubiquitination and degradation in human lung cancer H1299 cells. As shown in Figure 1a , co-transfection of MDM2 and p53 in p53 null H1299 cells promoted p53 degradation, and the Ring finger point mutant (C464A), which lacks the ubiquitin E3 ligase activity, was inert in destabilizing p53, as expected. Evidently, MDM2(D254-264) was also unable to destabilize p53 ( Figure 1a ). In addition, wild-type MDM2, but not MDM2(C464A), facilitated p53 ubiquitination. In contrast, MDM2(D254-264) exhibited a dramatically reduced ability in facilitating p53 ubiquitination (Figure 1b and Supplementary Figure 1) . Notably, MDM2(D254-264) exhibited a similar activity in selfubiquitination as compared to wild-type MDM2. MDM2(C464A), in sharp contrast, was totally inert in self-ubiquitination, resulting in dramatic accumulation of the mutant proteins (Figure 1c ). These data suggest that the 11 amino-acid module in the MDM2 CAD is (a) H1299 cells were co-transfected with p53, GFP and either wildtype MDM2, MDM2(D254-264) or MDM2(C464A) expression plasmids for 24 h. Equal amounts of total proteins were subjected to western blot analysis, as indicated. (b) H1299 cells were cotransfected with Myc-Ub, GFP, p53 and a variant MDM2 expression plasmid as indicated for 24 h and treated with MG132 for additional 6 h prior to collection. Cell lysates were subjected to western blot analysis for p53, MDM2 and GFP. (c) H1299 cells were co-transfected with Myc-Ub, GFP and an indicated MDM2 expression plasmid. 12 h after transfection, cells were split into two sets and grown for 24 h prior to treatment with or without MG132 for an additional 6 h. Cell lysates were subjected to western blot analyses, as indicated. (d) MDM2(D254-264) binds to p53 similarly as wild-type MDM2. H1299 cells were co-transfected with p53 and wild-type MDM2 or MDM2(D254-264). Cell lysates were immunoprecipitated using a p53 specific antibody (FL-393) or a control antibody (mouse IgG) followed by western blotting for MDM2.
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The central acidic domain of MDM2 is critical for gankyrin-mediated p53 ubiquitination It was recently shown that the MDM2 CAD can function as a second binding site for p53 in addition to the N terminus of MDM2 (Kulikov et al., 2006; Ma et al., 2006) . We therefore examined whether the reduced p53 ubiquitination by MDM2(D254-264) is due to the compromised MDM2-p53 interaction. As shown in Figure 1d , showed similar binding affinity for p53 as evidenced by co-immunoprecipitation (co-IP) experiments (Figure 1d ), suggesting that the impaired function of MDM2(D254-264) on p53 ubiquitination is likely through a defective interaction with certain cellular proteins rather than a direct impact on MDM2-p53 interaction. Indeed, CAD of MDM2 is known to interact with several proteins, including p300 (Grossman et al., 2003) , YY-1 (Sui et al., 2004) , ARF (Pomerantz et al., 1998; Zhang et al., 1998; Weber et al., 1999) , ribosomal protein L11 (Zhang et al., 2003) and KAP1 (Wang et al., 2005) . In particular, p300 and YY1 have been shown to significantly enhance MDM2-mediated p53 ubiquitination (Grossman et al., 2003; Sui et al., 2004) . We therefore examined whether the deletion of aa Figure 2 Deletion of Rb-binding module of MDM2 has little effect on p300 or YY1 but impairs the function of gankyrin in enhancing p53 ubiquitination. H1299 were co-transfected with p53, His-Ub and either wild-type MDM2 or MDM2(D254-264) in the presence of p300 (a) or YY1 (b) expression plasmids, as indicated. Twenty-four hours post transfection, cells were treated with MG132 for 6 h. Cell lysates were subjected to western blot analysis using a monoclonal antibody specific for p53 (DO-1) and for YY-1 using an antibody for HA. The input p53 protein levels were also examined by western blot analysis. Molecular weight markers are indicated. (c) H1299 cells were co-transfected with p53, Myc-Ub, GFP, gankyrin and wild-type MDM2 or MDM2(D254-264) expression plasmids. Cell lysates were subjected to western blot analysis as indicated. (d) Gankyrin enhances p53 interaction with wild-type MDM2 but not MDM2(D254-264). H1299 cells were transfected with p53 and wild-type MDM2 or MDM2(D254-264) with or without gankyrin expression plasmid. Equal amount of total protein was immunoprecipitated using antibody specific for p53 followed by western blot analysis for MDM2. Total protein (20 mg) derived from whole cell lysates (WCE) was analysed by western blot analysis as indicated. (e) MDM2(D254-264) interacts with gankyrin in vitro. Whole cell lysates from H1299 cells transfected with wild-type MDM2, MDM2(D254-264) or MDM2(D372-437) were subjected to GST-gankyrin pulldown followed by western blot analysis for MDM2. About 5% of total input protein was directly loaded as control for input. Comparable amounts of input GST-gankyrin fusion protein were confirmed by R-250 staining. (f) MDM2(D254-264) interacts with gankyrin in vivo. H1299 cells were co-transfected with HA-gankyrin and wild-type MDM2 or MDM2(D254-264). Cell lysates were immunoprecipitated using antibody specific for MDM2 followed by western blotting for HA.
254-264 in CAD affects the function of p300 or YY1 toward p53 ubiquitination. As shown in Figure 2a , p300 significantly enhanced MDM2-mediated p53 ubiquitination, in agreement with previous reports (Grossman et al., 2003) . Notably, p300 was also able to enhance the function of MDM2(D254-264) on p53 ubiquitination (Figure 2a) . Similarly, YY1 significantly enhanced p53 ubiquitination regardless of wild-type MDM2 or MDM2(D254-264) (Figure 2b ). These data indicate that neither p300 nor YY1 is responsible for the defective function of MDM2(D254-264) in p53 ubiquitination.
Recently, gankyrin, an oncoprotein frequently overexpressed in human cancers, has been reported to bind to MDM2 resulting in an increase of MDM2-p53 interaction and p53 ubiquitination/degradation (Higashitsuji et al., 2005) . We then investigated whether gankyrin plays a role in MDM2 CAD-dependent p53 ubiquitination. As expected, gankyrin stimulated p53 ubiquitination induced by MDM2. However, deletion of the 11 amino-acid module (aa 254-264) in CAD of MDM2 abolished the function of gankyrin in enhancing p53 ubiquitination ( Figure 2c ). To study the molecular basis on which gankyrin is defective in promoting MDM2(D254-264)-mediated p53 ubiquitination, we first examined the effect of gankyrin on MDM2-p53 interaction. As shown in Figure 2d , gankyrin increased p53 interaction with wild-type MDM2, but not MDM2(D254-264), as evidenced by co-IP experiments. It is conceivable that mutant MDM2 lacking the module (aa 254-264) may have a reduced affinity for gankyrin. To address this possibility, we performed GST pull-down analysis using GST-gankyrin and cell lysates derived from H1299 cells transiently expressing MDM2 or mutant MDM2(D254-264) and MDM2(D372-437), the latter of which is defective in gankyrin interaction as previously reported (Higashitsuji et al., 2005) . Evidently, MDM2(D254-264) showed comparable binding with gankyrin compared to wild-type MDM2. As expected, MDM2(D372-437) had substantially reduced affinity with GSTgankyrin (Figure 2e ), consistent with previous report (Higashitsuji et al., 2005) . Similar results were obtained from co-IP experiments (Figure 2f ). Taken together, these data indicate that CAD of MDM2 is critical for gankyrin in stimulating MDM2-mediated p53 ubiquitination, while it is not engaged in interaction with gankyrin.
Rb inhibits the function of gankyrin-MDM2 in p53 ubiquitination and degradation The observation that the 11 amino-acid module in the MDM2 CAD is critical for MDM2 function in p53 ubiquitination and degradation arises an interesting possibility that Rb may regulate MDM2 function toward p53 ubiquitination. To address this possibility, we first directly tested whether Rb affects p53 ubiquitination. As shown in Figure 3a , co-expression of Rb along with MDM2 and p53 in H1299 cells led to a significant reduction of MDM2-mediated p53 ubiquitination. In addition, co-expression of Rb effectively inhibits gankyrin-mediated p53 degradation (Figure3b and Supplementary Figure 2) . We then examined the MDM2-p53 interaction in the presence or absence of Rb. Interestingly, while gankyrin enhanced MDM2-p53 interaction, as shown previously (Higashitsuji et al., 2005) , Rb significantly inhibited MDM2-p53 interaction (Figure 3c ) even in the presence of gankyrin. These data suggest that Rb modulates the function of gankyrin-MDM2 complex in regulation of p53 stability.
We next investigated the molecular basis by which Rb modulates MDM2-gankyrin activity of p53 ubiquitination and degradation. We first examined the effect of Rb on the gankyrin-MDM2 interaction. As shown in Figure 4a , expression of Rb inhibits MDM2-gankyrin interaction as evidenced by GST-gankyrin pull down experiments. In contrast, Rb was unable to inhibit the MDM2 interaction with gankyrin(E182A) that bears a Figure 3 Rb inhibits MDM2-gankyrin mediated p53 ubiquitination. (a) H1299 cells were co-transfected with p53, myc-Ub, GFP and wild-type MDM2 or MDM2(D254-264) in the presence or absence of Rb expressing plasmid for 24 h and treated with MG132 for 6 h. Cell lysates were subjected to western blotting for p53, MDM2, Rb and GFP, respectively. (b) H1299 cells were cotransfected with GFP, p53, MDM2, gankyrin and Rb, as indicated, for 24 h. Cell lysates were subjected to western blot analysis. (c) Rb inhibits gankyrin-induced MDM2-p53 interaction. H1299 cells were co-transfected with HA-p53, gankyrin and Rb expressing plasmids, as indicated. Cell lysate was subjected to immunoprecipitation using an antibody specific for MDM2 (SMP14) followed by western blotting for p53 (anti-HA). 20 mg of total protein derived from whole cell lysates was analysed for protein expression, as indicated. Relative levels of MDM2-bound p53 were quantitated using densitometry.
Rb modulates MDM2/gankyrin in regulation of p53 W Qiu et al point mutation in the 178 L-X-C-X-E 182 motif and thus is defective in Rb interaction (Higashitsuji et al., 2000) . These data suggest that the physical interaction between Rb and gankyrin has a negative impact on MDM2-gankyrin complex formation. We next examined the effect of MDM2 on Rb-gankyrin interaction. As shown in Figure 4b , overexpression of MDM2 led to a significant reduction of Rb-gankyrin interaction, which is dependent on the physical interaction between MDM2 and Rb since MDM2(D254-264) had little effect under similar conditions. Again, these data suggest that the interplay between MDM2, Rb and gankyrin is critical for MDM2-gankyrin complex formation. To further investigate the significance of Rb-gankyrin interaction in regulating p53 ubiquitination and degradation, we co-transfected wild-type Rb or a mutant Rb defective in gankyrin interaction (Rb-9) (Dick and Dyson, 2003) along with p53 and MDM2 in the absence or presence of gankyrin. As shown in Figure 4c , gankyrin markedly enhanced p53 ubiquitination, as expected. Co-expression of Rb, but not Rb-9, significantly blocked gankyrin-stimulated p53 ubiquitination (Figure4c and Supplementary Figure 3) . Interestingly, Rb small pocket (RbSP), unable to bind to MDM2 (Sdek et al., 2004) , was also unable to inhibit p53 ubiquitination. However, the Rb C-pocket (Rb-C), which is necessary and sufficient for binding MDM2 (Sdek et al., 2004) , was fully capable of inhibiting p53 ubiquitination (Supplementary Figure 3) . Together, these data demonstrate that the physical interaction between Rb, MDM2 and gankyrin is essential in regulating p53 stability.
Ablation of Rb leads to an increase in MDM2-p53 interaction and p53 destabilization To examine the effect of Rb knockdown on p53 stability, we infected U2-OS or HepG2 cells with a recombinant retrovirus encoding shRNA specific for Rb or the retroviral vector. As shown in Figure 5a and Supplementary Figure 4 , knockdown of Rb led to a substantial reduction of p53 protein levels and a marked reduction of p21 protein levels, consistent with the reduced p53 activities. Furthermore, knockdown of Rb resulted in an increased MDM2-p53 interaction as evidenced by co-IP experiments (Figure 5b ). Importantly, Rb knockdown-induced p53 reduction was recovered by concomitant ablation of gankyrin (Figure 5c ). Moreover, inhibition of Rb led to a shortened p53 protein half-life (Figure 5d ). Taken together, these data indicate that lack of Rb elevates MDM2-gankyrin activity for p53 ubiquitination and degradation.
Knockdown of Rb desensitizes cancer cells in response to chemotherapy
Given that knockdown of Rb destabilizes p53, we next investigated the effect of Rb ablation on cellular response to chemotherapeutic drug treatment of cancer cells. U2-OS cells stably expressing Rb shRNA showed a significant decrease in cell death upon doxorubicin treatment, concomitant with a decrease in p53 protein levels (Figure 6a ). In addition, knockdown of Rb in HepG2 cells treated with cisplatin led to a markedly reduced cleavage of either poly (ADP-ribose) polymerase (PARP) or Caspase-3, a hallmark of activation of apoptosis (Figure 6b) . Furthermore, treatment of HepG2 cells with cisplatin or mitomycin C resulted in apoptosis as evidenced by FACS analysis, which was significantly reduced in the cells expressing Rb shRNA (Figure 6c ). These data strongly suggest that lack of Rb desensitizes cancer cells for apoptosis upon chemotherapeutic drug treatment.
Discussion
It is well known that p53 and Rb pathways crosstalk, which plays a critical role in impacting cancer cell Figure 4 Rb inhibits MDM2-gankyrin interaction and attenuates the function of gankyrin on p53 ubiquitination. (a) H1299 cells were co-transfected with pCMV-MDM2 and pCMV-Rb for 24 h and treated with MG132 for 6 h. Cell lysates were incubated with GST-gankyrin or GST-gankyrin(E182A) followed by western blotting for MDM2. About 5% of input proteins (WCE) were directly loaded on the gel as control. Comparable amounts of GST fusion proteins were visualized by R-250 staining. (b) Whole cell lysates derived from H1299 cells transiently expressing Rb were incubated with GST-gankyrin in the presence of purified 200 ng of wild-type MDM2 or MDM2(D254-264) followed by western blot analysis for Rb. Input of MDM2 and GST-gankyrin proteins was assessed by western blotting or R250 staining, respectively. (c) H1299 cells were co-transfected with p53, Myc-Ub, MDM2, gankyrin and Rb or Rb-9 expression plasmids as indicated. Cells were treated with MG132 6 h prior to collection. Cell lysates were immunoprecipitated using a specific antibody for p53 (DO-1) and followed by western blotting for Myc-tagged Ub. WCE were used in parallel for protein expression by western blotting as indicated.
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W Qiu et al proliferation and survival. In this study, we demonstrate that Rb critically modulates MDM2-gankyrin activity for p53 ubiquitination/degradation and thus plays a direct role in the sensitivity of human cancer cells upon chemotherapeutic agents. First, Rb inhibits gankyrinmediated facilitation of MDM2-p53 interaction, and consequently, p53 ubiquitination and degradation. Importantly, this action of Rb requires a physical interaction between Rb, gankyrin and MDM2. Second, knockdown of Rb enhances the MDM2-p53 interaction and p53 destabilization in a gankyrindependent manner. Furthermore, Rb ablation results in reduced apoptotic response upon chemotherapeutic drug treatment, concomitant with reduced p53 protein levels. CAD of MDM2 is critical for Rb-mediated regulation of p53 stability. Notably, the MDM2 CAD has been shown as an interaction module for a group of proteins, including ARF, p300, YY-1, KAP1 and L11. As shown in this study, p300 and YY1 facilitates ubiquitination of p53, consistent with previous reports (Grossman et al., 2003; Sui et al., 2004) . However, Rb-dependent regulation of p53 stability does not engage p300 or YY1. In contrast, deletion of the Rb-binding motif in the MDM2 CAD significantly impairs the stimulatory function of gankyrin on p53 ubiquitination and degradation. Since the MDM2 CAD has been reported as a second binding site for p53 (Kulikov et al., 2006; Ma et al., 2006) , it would be conceivable that deletion of the Rb-binding domain of MDM2 may alter its ability for interaction with p53 or gankyrin, a consequence that would account for the impaired function of MDM2 on p53 ubiquitination and degradation. However, our data show that deletion of the Rb-binding domain of MDM2 does not affect its interaction with p53 or gankyrin, suggesting that the impaired activity of the mutant MDM2 is not due to an altered interaction between MDM2 and p53 or gankyrin. Rb ablation leads to an increase in MDM2-p53 interaction and p53 destabilization. (a) Protein expression from U2-OS or HepG2 cells stably expressing Rb shRNA or empty vector (pMSCV) was analysed by western blot analyses. The p53 protein levels were quantitated using densitometry scanning and presented as fold differences, where the ratio of p53 protein over actin in the control cells was arbitrarily set as onefold. (b) U2-OS cells stably expressing Rb shRNA or pMSCV were treated with MG132 for 6 h prior to collection. Cell lysates were immunoprecipitated for MDM2 followed by western blotting for p53. Whole cell lysates (WCE) were analysed by western blotting as indicated. (c) HepG2 cells stably expressing Rb shRNA were infected with retroviral gankyrin shRNA or vector. Cell lysates were analysed by western blotting as indicated. (d) U2OS cells stably expressing Rb shRNA or pMSCV vector were treated with cycloheximide (CHX) and collected at the indicated time points, followed by western blotting analysis. Amounts of p53 protein were quantitated using densitometry analysis and plotted as shown.
Rb modulates MDM2/gankyrin in regulation of p53 W Qiu et al Then, how does the deletion of the Rb-binding domain affect MDM2-mediated p53 ubiquitination and degradation? The deletion does not affect MDM2 binding to p53 or gankyrin, but it does affect gankyrinmediated facilitation of MDM2-p53 interaction. Since MDM2 interacts with both Rb and gankyrin which also interacts with Rb, it is conceivable that MDM2(D254-264) defective in Rb binding leads to an increased pool of Rb, which in turn binds to and inhibits the MDM2-gankyrin complex resulting in a reduced p53-MDM2 interaction. Indeed, our data suggest that this is likely the case. In addition, our model (Figure 7 ) would predict that Rb inhibits p53 ubiquitination, and Rb ablation destabilizes p53 in a gankyrin-dependent manner, both of which, in fact, are also demonstrated in this study. Furthermore, accelerated Rb degradation by overexpression of MDM2 or gankyrin would lead to derepression of Rb on MDM2/gankyrin for p53 ubiquitination (Figure 7 ). This feedback loop would serve to assure efficient p53 degradation under certain pathological circumstances in which MDM2 or gankyrin are overproduced in a subset of human cancers.
The role of Rb in modulating p53 stability may have important implications. Upon chemotherapeutical drug treatment, cancer cells with ablation of Rb display a reduced sensitivity for the drug-induced apoptosis, concomitant with a markedly reduced cleavage of PARP and casapase-3. It is well known that many cancer cells have inactivation of either p53 or Rb. However, inactivation of both p53 and Rb has cooperative effects in tumor development resulting in increased tumor Figure 6 Rb ablation desensitizes cancer cells in chemotherapeutic drug-induced apoptosis. (a) U2-OS cells stably expressing Rb shRNA or empty vector (pMSCV) were treated with 1 mM doxorubicin for 48 h. Cell viability was determined by trypan blue exclusion assay. Three independent experiments were performed and presented as mean ± s.d. Protein expression was determined by western blot analysis. (b) HepG2 cells stably expressing Rb shRNA or control vector (pMSCV) were treated with 50 mM cisplatin for 2 h and then grown for 20 h in drug-free medium. Whole cell lysates were examined by western blot analyses as indicated. (c) HepG2 cells stably expressing Rb shRNA or control vector (pMSCV) were treated in the absence or presence of 50 mM cisplatin for 2 h and additional 20 h in drug-free medium or 5 mg ml À1 mitomycin C for 24 h. Cells were subjected to FACS analysis. The bottom panel shows data derived from three independent experiments performed in duplicates and the statistic analyses. recurrence and decreased survival of patients (Xu et al., 1996; Cordon-Cardo et al., 1997) . Further understanding the role of Rb in chemosensitivity in cancer cells may therefore be significant in directing cancer chemotherapy.
It is important to point out that loss of Rb expression or inactivation of Rb by hyperphosphorylation or other means can lead to the release of E2F1, which in turn activates ARF resulting in MDM2 inhibition and p53 stabilization, a consequence in contrast to a positive role of Rb in modulating p53 stability as demonstrated in this study. Thus, Rb may play dual roles in a delicate balance of controlling p53 activity. However, the E2F-ARF-MDM2-p53 pathway is defective in many human tumors and cancers due to genetic alterations that inactivate ARF. Therefore, it is conceivable that the Rb status would be critically important for p53 abundance and activity upon chemotherapy in these types of tumors and cancers lacking p16 INK1 /ARF. Notably, the role of Rb in apoptosis in normal cells appears complex. While Rb-deficient mice undergo massive apoptosis in central nervous system, Rb has been shown to play a critical role in regulation of apoptosis during embryonic development through a cellautonomous as well as noncell-autonomous fashion (Lipinski et al., 2001; de Bruin et al., 2003; Wu et al., 2003) . Loss of Rb also leads to the activation of E2Fs, which regulate a set of genes involved in apoptosis, adding another layer of complexity. Thus, the role of Rb in apoptosis could be quite different in normal cells versus cancers where several key components in p53 and Rb pathways are deregulated.
Materials and methods
Cell culture and plasmid construction H1299, U2-OS and HepG2 cells were maintained in Dulbecco's modified Eagles medium supplemented with 10% fetal bovine serum and 1% penicillin G/streptomycin sulfate (Invitrogen Inc., Carlsbad, CA, USA) at 37 1C in a humidified 5% CO 2 incubator. pFAD-Rb-9 (I753A, N757A and M761A) construct was kindly provided by Dr Nick Dyson. p-BamNeo-MDM2 (from Dr Jiandong Chen) was used to generate mutations in CAD by site-directed mutagenesis in accordance with the manufacture's instruction (Stratagene Inc., La Jolla, CA, USA). All mutants were confirmed by DNA sequencing.
Transfection, retroviral infection and RNA interference Transient transfections were carried out using lipofectamine 2000 transfection reagent (Invitrogen Inc., Carlsbad, CA, USA). To analyse the activity of MDM2 on p53 ubiquitination and degradation, H1299 cells in 60 mm culture dishes were cotransfected with 1 mg of pCMV-MDM2 or MDM2(D254-264), 100 ng of pcDNA-HA-p53, 100 ng of pEGFP and 1 mg of pCMV-Myc-Ub (or pCMV-His-Ub) where appropriate. To analyse the function of the MDM2 modifier (p300, YY-1, gankyrin and Rb) on MDM2-mediated p53 ubiquitination and degradation, H1299 cells were co-transfected with 100 ng of pcDNA-HA-p53, 100 ng of pEGFP, 1 mg of pCMV-MDM2 or MDM2(D254-264), 1 mg of an indicated modifier plasmid and 1 mg of pCMV-Myc-Ub (or pCMV-His-Ub) where appropriate. To analyse p53 ubiquitination, 24 h after transfection, cells were treated with MG132 (20 mM) for 6 h prior to cell collection. To examine the in vivo interaction of MDM2, p53 and gankyrin by co-IP experiments, H1299 cells in 100 mm culture dishes were co-transfected with 4 mg of MDM2, 1 mg of p53 and 4 mg of gankyrin expressing plasmids using lipofectamine 2000 unless otherwise indicated. Cells were treated with MG132 (20 mM) for 6 h prior to cell collection.
Knockdown experiments were carried out by retroviral based short hairpin RNAi. Retrovirus were amplified and concentrated as described (Sdek et al., 2005) . Briefly, 293FT cells were co-transfected with 4 mg of pMSCV-Rb shRNA construct or pSF-hygro/GFP-gankyrin shRNA plasmids along with 4 mg of pol/gag/env viral packaging plasmids by lipofectamine 2000. Forty-eight hours after transfection, culture medium were collected, filtered and subjected to ultra centrifugation at 25 000 rpm for 90 min at 4 1C. Cells were infected with concentrated virus particles. Forty-eight hours post infection, cells were selected by puromycin (1 mg ml À1 ; Sigma, St Louis, MO, USA) or hygromycin (200 mg ml À1 ; Cellgro, Lawrence, KA, USA) for additional 48 h prior to subsequent experiments.
Western blot analysis Cells were lysed in EBC250 lysis buffer (50 mM Tris-HCl pH7.4, 250 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mM PMSF, 2 mg ml À1 leupeptin and 2 mg ml À1 aprotinin). Equal amounts of total protein (30 mg) were separated in 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels, transferred to polyvinylidene difluoride membrane and hybridized to an appropriate primary antibody and HRP-conjugated secondary antibody for subsequent detection by ECL (Amersham, Buckinghamshire, UK). To analyse p53 ubiquitination, 60 mg of total proteins were separated in 7.5% SDS-PAGE gels. Specific antibodies were used to detect MDM2 (SMP14, Santa Cruz Biotechnology, Santa Cruz, CA, USA), Rb (G3-245, BD PharMingen, San Jose, CA, USA), GFP (FL, Santa Cruz Biotechnology), p53 (DO-1, Santa Cruz Biotechnology; Fl-393, Santa Cruz Biotechnology), p21 (SXM-30, BD PharMingen), HA (Y-11, Santa Cruz Biotechnology), Actin (C-11, Santa Cruz Biotechnology), gankyrin (H231, Santa Cruz Biotechnology), procaspase3 (29E10B6C10, from Dr J Yuan at Harvard Medical School), active caspase 3 (H176, Santa Cruz Biotechnology), anti-myc tag (9B11, Cell Signaling, Danvers, MA, USA). GST pull down and co-immunoprecipitation GST pull down procedure was used as previously described (Sdek et al., 2004) . H1299 cells were transiently transfected with wild-type MDM2 or MDM2(D254-264) and treated with MG-132 (20 mM) for 6 h prior to cell collection. Cells were lysed in the binding buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 10% Glycerol, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mM PMSF, 2 mg ml À1 leupeptin, and 2 mg ml À1 aprotinin). Comparable amounts of MDM2 proteins were used in GST pull down or co-IP procedures. For co-IP experiments, cell lysates were precleared with 50 ml of protein-A beads. Approximately 1 mg of total protein in 1 ml binding buffer containing 10 mg of an indicated primary antibody was incubated for 3 h or overnight prior to addition of secondary antibody and subsequently, a mixture of protein A/GSepharose beads. Immunoprecipitated protein complexes proteins were subjected to western blot analysis using an appropriate antibody as indicated. For GST pull-down experiments, comparable amounts of GST-gankyrin or GST immobilized on glutathione-Sepharose beads were suspended in 600 ml binding buffer and incubated with cell lysates containing comparable amounts of MDM2 or Rb proteins, as indicated. After 3 h incubation at 4 1C, the beads were washed four times with binding buffer. Proteins were separated on 10% SDS-PAGE followed by western blot analysis. To assess the effect of MDM2 on the Rb-gankyrin interaction in vitro, MDM2 protein was purified as described (Sdek et al., 2005) . Briefly, H1299 cells were transfected with pCMV-MDM2 or MDM2(D254-264) for 24 h and treated with 20 mM MG132 for additional 6 h prior to collection. Cell lysates were immunoprecipitated using SMP14 antibody immobilized on Agarose (Santa Cruz Biotechnology). The Agarose beads were incubated with 0.1 M glycine HCl at pH 3.5 for 5 min at room temperature. The supernatant was neutralized with a buffer (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl). The eluted MDM2 proteins were quantitated and stored at À20 1C.
Cell death and FACS analysis Stable U2-OS cells were treated with doxorubicin (1 mM, Sigma) for 48 h. Both floating and adherent cells were collected and subjected to trypan blue exclusion assay. At least 100 cells per field for four fields were counted. Percentage of cell death was calculated as the ratio of dead cells over total cells counted. To analyse the effects of Rb knockdown on chemotherapeutic agent-induced apoptosis, stable HepG2 cells in 80-90% confluence were treated with 50 mM cisplatin for 2 h and cells were in drug-free medium for additional 20 h. For mitomycin C treatment, stable HepG2 cells were treated with 5 mg ml À1 mitomycin C for 24 h before harvest. Both floating and adherent cells were collected and fixed in 70% ethanol at 4 1C overnight. Cells were resuspended in PI staining solution (0.1% sodium citrate, 0.3% NP-40, 100 mg ml À1 RNAse A and 50 mg ml À1 propidium iodide), and subjected to FACS analysis using BD FACscan (80900) At least three independent experiments in duplicates were performed. Statistic analysis was performed using Student's t-test.
